ADARx Pharmaceuticals develops a modality-agnostic RNA targeting platform that utilizes base editing of mRNA transcripts to create therapeutics for genetic, cardiometabolic, and central nervous system diseases. The company aims to provide effective treatments for intractable diseases by leveraging oligonucleotides for inhibition, degradation, and editing, along with advanced delivery technologies.
Funding
$352.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCTCFounders
Product
Problem
Many genetic, cardiometabolic, and central nervous system diseases lack effective treatments due to the difficulty of targeting RNA transcripts directly. Traditional therapeutic approaches often struggle to selectively modulate gene expression or correct disease-causing mutations at the RNA level.
Solution
ADARx Pharmaceuticals is developing a modality-agnostic RNA targeting platform that uses base editing of mRNA transcripts to create therapeutics for a range of diseases. The platform leverages oligonucleotides for inhibition, degradation, and editing of RNA, combined with advanced delivery technologies to reach target tissues. This approach allows for selective modulation of gene expression and correction of disease-causing mutations at the RNA level, offering potential treatments for intractable diseases. The company is focused on building a pipeline of therapeutics to address unmet medical needs in genetic, cardiometabolic, and central nervous system diseases.
Target Audience
The primary target audience includes patients suffering from genetic, cardiometabolic, and central nervous system diseases with limited or no existing treatment options.
Features
- Modality-agnostic RNA targeting platform applicable to various therapeutic approaches
- Utilizes base editing of mRNA transcripts for precise gene modulation
- Employs oligonucleotides for inhibition, degradation, and editing of RNA
- Advanced delivery technologies to enhance therapeutic efficacy and target specificity
- Focus on genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases